KR20060123688A - 캔디다 알비칸스의 검출용 핵산 탐침 - Google Patents
캔디다 알비칸스의 검출용 핵산 탐침 Download PDFInfo
- Publication number
- KR20060123688A KR20060123688A KR1020060111598A KR20060111598A KR20060123688A KR 20060123688 A KR20060123688 A KR 20060123688A KR 1020060111598 A KR1020060111598 A KR 1020060111598A KR 20060111598 A KR20060111598 A KR 20060111598A KR 20060123688 A KR20060123688 A KR 20060123688A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- seq
- detecting
- present
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004711 Nucleic Acid Probes Proteins 0.000 title claims abstract description 270
- 239000002853 nucleic acid probe Substances 0.000 title claims abstract description 270
- 238000001514 detection method Methods 0.000 title claims description 68
- 241000222122 Candida albicans Species 0.000 title claims description 20
- 229940095731 candida albicans Drugs 0.000 title description 3
- 239000012472 biological sample Substances 0.000 claims abstract description 250
- 239000000203 mixture Substances 0.000 claims abstract description 213
- 239000000523 sample Substances 0.000 claims description 439
- 150000007523 nucleic acids Chemical class 0.000 claims description 398
- 102000039446 nucleic acids Human genes 0.000 claims description 395
- 108020004707 nucleic acids Proteins 0.000 claims description 395
- 108091033319 polynucleotide Proteins 0.000 claims description 245
- 102000040430 polynucleotide Human genes 0.000 claims description 245
- 239000002773 nucleotide Substances 0.000 claims description 243
- 125000003729 nucleotide group Chemical group 0.000 claims description 243
- 238000009396 hybridization Methods 0.000 claims description 231
- 238000005406 washing Methods 0.000 claims description 155
- 239000000872 buffer Substances 0.000 claims description 107
- 230000002441 reversible effect Effects 0.000 claims description 102
- 238000006243 chemical reaction Methods 0.000 claims description 82
- 238000000018 DNA microarray Methods 0.000 claims description 74
- 239000007787 solid Substances 0.000 claims description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 abstract description 21
- 108700022487 rRNA Genes Proteins 0.000 abstract description 15
- 208000035473 Communicable disease Diseases 0.000 abstract description 12
- 230000002458 infectious effect Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 502
- 241000894006 Bacteria Species 0.000 description 213
- 239000000243 solution Substances 0.000 description 145
- 238000000034 method Methods 0.000 description 107
- 239000002585 base Substances 0.000 description 70
- 239000000047 product Substances 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 238000003752 polymerase chain reaction Methods 0.000 description 34
- 241000606125 Bacteroides Species 0.000 description 30
- 238000012360 testing method Methods 0.000 description 24
- 230000000295 complement effect Effects 0.000 description 22
- 241000191992 Peptostreptococcus Species 0.000 description 19
- 241000233866 Fungi Species 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 206010014665 endocarditis Diseases 0.000 description 17
- 239000011521 glass Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 108091023242 Internal transcribed spacer Proteins 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 241000589291 Acinetobacter Species 0.000 description 14
- 241000193403 Clostridium Species 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 241000588770 Proteus mirabilis Species 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 13
- 244000052769 pathogen Species 0.000 description 13
- 241000194033 Enterococcus Species 0.000 description 12
- 241000192016 Finegoldia magna Species 0.000 description 12
- 201000009906 Meningitis Diseases 0.000 description 12
- 241000588767 Proteus vulgaris Species 0.000 description 12
- 241000191963 Staphylococcus epidermidis Species 0.000 description 12
- 238000004925 denaturation Methods 0.000 description 12
- 230000036425 denaturation Effects 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 241000605952 Fusobacterium necrophorum Species 0.000 description 11
- 241000606790 Haemophilus Species 0.000 description 11
- 241000588915 Klebsiella aerogenes Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 206010013023 diphtheria Diseases 0.000 description 11
- 229940007042 proteus vulgaris Drugs 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 241000588653 Neisseria Species 0.000 description 10
- 241000194019 Streptococcus mutans Species 0.000 description 10
- 229940096118 ella Drugs 0.000 description 10
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 10
- 208000031729 Bacteremia Diseases 0.000 description 9
- 241000207210 Cardiobacterium hominis Species 0.000 description 9
- 241000186216 Corynebacterium Species 0.000 description 9
- 241000589242 Legionella pneumophila Species 0.000 description 9
- 241000186779 Listeria monocytogenes Species 0.000 description 9
- 241000588655 Moraxella catarrhalis Species 0.000 description 9
- 241000588650 Neisseria meningitidis Species 0.000 description 9
- 206010031252 Osteomyelitis Diseases 0.000 description 9
- 241000607142 Salmonella Species 0.000 description 9
- 241000193998 Streptococcus pneumoniae Species 0.000 description 9
- 241000222126 [Candida] glabrata Species 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 229940115932 legionella pneumophila Drugs 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108020004463 18S ribosomal RNA Proteins 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 8
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 8
- 241000607598 Vibrio Species 0.000 description 8
- 206010000269 abscess Diseases 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940092559 enterobacter aerogenes Drugs 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000004575 Infectious Arthritis Diseases 0.000 description 7
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 7
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 7
- 208000004020 Brain Abscess Diseases 0.000 description 6
- 102000016943 Muramidase Human genes 0.000 description 6
- 108010014251 Muramidase Proteins 0.000 description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960000274 lysozyme Drugs 0.000 description 6
- 239000004325 lysozyme Substances 0.000 description 6
- 235000010335 lysozyme Nutrition 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 206010007882 Cellulitis Diseases 0.000 description 5
- 241000193163 Clostridioides difficile Species 0.000 description 5
- 206010033078 Otitis media Diseases 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 206010048038 Wound infection Diseases 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000007846 asymmetric PCR Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- -1 polystylene Substances 0.000 description 5
- 201000001223 septic arthritis Diseases 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 206010014568 Empyema Diseases 0.000 description 4
- 206010028885 Necrotising fasciitis Diseases 0.000 description 4
- 241001444167 Picus Species 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000007970 necrotizing fasciitis Diseases 0.000 description 4
- 206010034674 peritonitis Diseases 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 201000009890 sinusitis Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010053555 Arthritis bacterial Diseases 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 3
- 241000207206 Cardiobacterium Species 0.000 description 3
- 206010009137 Chronic sinusitis Diseases 0.000 description 3
- 241000589519 Comamonas Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 206010048461 Genital infection Diseases 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 206010024652 Liver abscess Diseases 0.000 description 3
- 206010048685 Oral infection Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 241001148470 aerobic bacillus Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000014670 detection of bacterium Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 206010014801 endophthalmitis Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 201000001245 periodontitis Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010056519 Abdominal infection Diseases 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 241000186041 Actinomyces israelii Species 0.000 description 2
- 241000722954 Anaerobiospirillum succiniciproducens Species 0.000 description 2
- 241001464890 Anaerococcus prevotii Species 0.000 description 2
- 241000272522 Anas Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- 241001135228 Bacteroides ovatus Species 0.000 description 2
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 2
- 241000606215 Bacteroides vulgatus Species 0.000 description 2
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241001600125 Delftia acidovorans Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000588878 Eikenella corrodens Species 0.000 description 2
- 241000589566 Elizabethkingia meningoseptica Species 0.000 description 2
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000760643 Homo sapiens Carbonic anhydrase 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000588749 Klebsiella oxytoca Species 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000001731 Lemierre syndrome Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000588814 Ochrobactrum anthropi Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 2
- 206010048984 Pancreatic abscess Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000605894 Porphyromonas Species 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000123713 Sutterella wadsworthensis Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000025255 bacterial arthritis Diseases 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000003516 breast abscess Diseases 0.000 description 2
- 208000032343 candida glabrata infection Diseases 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 108020004565 5.8S Ribosomal RNA Proteins 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 101150058502 Acaca gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000606828 Aggregatibacter aphrophilus Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010004050 Bacterial pericarditis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100024650 Carbonic anhydrase 3 Human genes 0.000 description 1
- 206010008685 Chondritis Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010060803 Diabetic foot infection Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 206010061846 Extradural abscess Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000760630 Homo sapiens Carbonic anhydrase 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000022351 Human Bites Diseases 0.000 description 1
- 241000889779 Hydromonas Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001251074 Imperator Species 0.000 description 1
- 208000000523 Infected Aneurysm Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- 241000589014 Kingella kingae Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000037426 Palatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 208000001143 Periodontal Abscess Diseases 0.000 description 1
- 206010034649 Peritoneal abscess Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036422 Postpartum sepsis Diseases 0.000 description 1
- 208000020264 Puerperal Infection Diseases 0.000 description 1
- 206010051071 Purulent pericarditis Diseases 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010044016 Tooth abscess Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000024035 chronic otitis media Diseases 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 201000003107 cutaneous diphtheria Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 201000000165 epidural abscess Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- WAHQBNXSPALNEA-UHFFFAOYSA-L lithium succinate Chemical compound [Li+].[Li+].[O-]C(=O)CCC([O-])=O WAHQBNXSPALNEA-UHFFFAOYSA-L 0.000 description 1
- 229960004254 lithium succinate Drugs 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 201000001231 mediastinitis Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- PJPOCNJHYFUPCE-UHFFFAOYSA-N picen-1-ol Chemical compound C1=CC=CC2=C(C=CC=3C4=CC=C5C=CC=C(C=35)O)C4=CC=C21 PJPOCNJHYFUPCE-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
- 하기 염기 서열을 포함한 핵산 분자로 이루어진 그룹 중에서 선택된 분리된 핵산 분자:TCAAGAACGAAAGTT (C.alic 006, 서열번호 398);AAGGATTGACAGATT (C.alic 007, 서열번호 399); 및CATTAATCAAGAACG (C.alic 008, 서열번호 400).
- 제 1 항의 서열번호 398 내지 400중 어느 하나의 염기 서열을 포함한 핵산 분자를 포함하는 캔디다 알비칸스 진균의 검출용 핵산 탐침.
- 제 1항의 서열번호 398 내지 400중 어느 하나의 염기 서열을 포함한 핵산 분자를 포함하는 캔디다 알비칸스 진균의 검출용 핵산 탐침을 포함한 조성물.
- (a) 제 1항의 서열번호 398 내지 400중 어느 하나의 염기 서열을 포함한 핵산 분자를 포함하는 캔디다 알비칸스 진균의 검출용 핵산 탐침을 포함한 조성물; (b) 임의로 생물학적 시료중의 폴리핵산을 증폭하는데 사용하는 전방향과 역방향 프라이머 쌍; (c) 상기 조성물에 함유된 탐침과 생물학적 시료중에 존재하는 폴리핵산 또는 이의 증폭된 산물사이에 혼성화 반응을 유도하는 완충액 또는 이러한 완충액을 생성하는데 필요한 성분; (d) 적당한 세척 조건하에서 형성된 하이브리드를 세척하기 위한 용액 또는 이러한 용액을 생성하는데 필요한 성분; 및 (e) 임의로 앞서 형성된 하이브리드를 검출하는 수단을 포함함을 특징으로 하여, 생물학적 시료에서 캔디다 알비칸스 진균을 검출 및 동정하기 위한 키트.
- 제 1항의 서열번호 398 내지 400중 어느 하나의 염기 서열을 포함한 핵산 분자를 포함하는 캔디다 알비칸스 진균의 검출용 핵산 탐침이 고체 지지체에 고정된 DNA 칩.
- (a) 임의로 생물학적 시료로부터 중에 존재하는 폴리핵산을 분리 및/또는 농축하고, (b) 임의로 폴리핵산을 적절한 전방향과 역방향 프라이머 쌍으로 증폭하고; (c) 상기 단계 (a) 및 (b)의 폴리핵산을 제 1 항의 서열번호 398 내지 400중 어느 하나의 염기 서열을 포함한 핵산 분자를 포함하는 캔디다 알비칸스 진균의 검출용 핵산 탐침을 포함한 조성물과 적절한 혼성화 및 세척 조건하에서 접촉시키고; (d) 상기 (c) 단계에서 형성된 하이브리드를 검출하고; (e) 상기 (d) 단계에서 얻은 상이한 혼성화 시그날로부터 시료에 존재하는 균주를 동정함을 특징으로 하여, 상기 생물학적 시료중에서 캔디다 알비칸스 진균을 검출 및 동정하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060111598A KR100781559B1 (ko) | 2006-11-13 | 2006-11-13 | 캔디다 알비칸스의 검출용 핵산 탐침 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060111598A KR100781559B1 (ko) | 2006-11-13 | 2006-11-13 | 캔디다 알비칸스의 검출용 핵산 탐침 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047018087A Division KR100781558B1 (ko) | 2002-05-09 | 2003-05-09 | 엑티노마이세스 이스라엘의 검출용 핵산 탐침 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060123688A true KR20060123688A (ko) | 2006-12-04 |
KR100781559B1 KR100781559B1 (ko) | 2007-12-03 |
Family
ID=37728605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060111598A Expired - Fee Related KR100781559B1 (ko) | 2006-11-13 | 2006-11-13 | 캔디다 알비칸스의 검출용 핵산 탐침 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100781559B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2106450A1 (en) * | 2007-01-08 | 2009-10-07 | Medigenes Co., Ltd. | Dna chip for detection of escherichia coli |
-
2006
- 2006-11-13 KR KR1020060111598A patent/KR100781559B1/ko not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2106450A1 (en) * | 2007-01-08 | 2009-10-07 | Medigenes Co., Ltd. | Dna chip for detection of escherichia coli |
EP2106450A4 (en) * | 2007-01-08 | 2010-03-10 | Medigenes Co Ltd | DNA CHIP TO DETECT ESCHERICHIA COLI |
Also Published As
Publication number | Publication date |
---|---|
KR100781559B1 (ko) | 2007-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20050100407A (ko) | 비바이러스 유기체의 검출용 핵산 탐침 | |
KR100617647B1 (ko) | 아시네토박터 바우마니 균의 검출용 dna 칩 | |
KR20050084547A (ko) | 푸소박테리움 네크로포룸 균의 검출용 dna 칩 | |
KR20060123688A (ko) | 캔디다 알비칸스의 검출용 핵산 탐침 | |
KR20060123687A (ko) | 에로모나스 하이드로필라의 검출용 핵산 탐침 | |
KR20050085994A (ko) | 코마모나스 아시도보란스 균의 검출용 dna 칩 | |
KR20050086967A (ko) | 펩토스트렙토코코스 프레보티 균의 검출용 dna 칩 | |
KR20050086972A (ko) | 해모필러스 아프로필라스 균의 검출용 dna 칩 | |
KR20050086970A (ko) | 엔테로박터 에어로게네스 균의 검출용 dna 칩 | |
KR20050086974A (ko) | 브란하멜라 카타르할리스 균의 검출용 dna 칩 | |
KR20050084543A (ko) | 클로스트리디움 람모섬 균의 검출용 dna 칩 | |
KR20050084544A (ko) | 코리네박테리움 디프테리애 균의 검출용 dna 칩 | |
KR20050084545A (ko) | 오크로박트룸 안트로피 균의 검출용 dna 칩 | |
KR20050084546A (ko) | 포피로모나스 진지발리스 균의 검출용 dna 칩 | |
KR20050084548A (ko) | 킨젤라 킨갭 균의 검출용 dna 칩 | |
KR20050084549A (ko) | 클로스트리디움 디프실 균의 검출용 dna 칩 | |
KR20050084542A (ko) | 박테로이데스 프라질리스 균의 검출용 dna 칩 | |
KR20050086973A (ko) | 나이세리아 고노헤아 균의 검출용 dna 칩 | |
KR20050086000A (ko) | 박테로이데스 불가투스 균의 검출용 dna 칩 | |
KR20050085997A (ko) | 스트렙토코커스 뮤탄스 균의 검출용 dna 칩 | |
KR20050085998A (ko) | 박테로이데스 테타이오타오미크론 균의 검출용 dna 칩 | |
KR20050085999A (ko) | 아이케넬라 코로덴스 균의 검출용 dna 칩 | |
KR20050085996A (ko) | 펩토스트렙토코커스 마그누스 균의 검출용 dna 칩 | |
KR20050086964A (ko) | 언에어로비오스피리룸 숙시니시프로더센스 균의 검출용dna 칩 | |
KR20050086965A (ko) | 카디오박테리움 호미니스 균의 검출용 dna 칩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20061113 Patent event code: PA01071R01D |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070206 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20070827 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20071127 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20071128 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20101129 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20111129 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20111129 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20121128 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20121128 Start annual number: 6 End annual number: 6 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |